Table 2.
Autoimmunity in NOD.aire−/− mice treated with innate immune stimuli
| Treatment | Pathway | Incidence | Wasting, day | Clinical scores |
|---|---|---|---|---|
| Untreated | — | 8/8 | 44, 44, 46, 50, 52, 58, 64, 72 | 4, 7, 7, 8, 9, 9, 10, 11 |
| LPS | TLR-4 | 3/3 | 60, 64, 79 | 8, 9, 16 |
| poly(I:C) | TLR-3 | 4/4 | 42, 54, 62, 62 | 8, 9, 10, 12 |
| poly(I:C), rep | TLR-3 | 4/6 | 47, 49, 57, 57, 102,* 105* | 2, 3, 8, 10, 10, 12 |
| CpG | TLR-9 | 4/5 | 25, 44, 57, 67, 105* | 0, 7, 7, 10, 21 |
| poly(I:C) and CpG, rep | TLR-3 and TLR-9 | 3/3 | 38, 50, 55 | 7, 12, 15 |
| Proteoglycan, rep | TLR-2 | 3/3 | 55, 64, 72 | 11, 11, 16 |
| PAM3CSK4 | TLR-2 | 2/4 | 57, 59, 104,* 104* | 8, 10, 11, 17 |
| PAM3CSK4, rep | TLR-2 | 3/3 | 48, 57, 67 | 12, 15, 16 |
| Zymosan | TLR-2/dectin-1 | 3/3 | 55, 64, 77 | 9, 15, 17 |
| β-1,3-glucan | Dectin-1 | 3/3 | 60, 66, 66 | 7, 8, 9 |
| Muramyl dipeptide | NOD-2 | 3/3 | 44, 51, 51 | 5, 5, 11 |
| Anti-CD40 | CD40 | 6/6 | 41, 45, 47, 48, 49, 51 | 7, 8, 9, 9, 10, 11 |
| Cyclophosphamide | Lymphopenia | 4/4 | 50, 70, 61, 82 | 8, 9, 10, 11 |
| CFA | ? | 3/3 | 43, 43, 67 | 8, 11, 13 |
Mice did not waste before termination of experiment. rep, repeated administrations. CFA, complete Freund's adjuvant.
*Survival to end point of study.